Amarin Corporation PLC AMRN
- Market cap
- $283.6M
- P/E
- 0.0×
Follow AMRN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.80 | 56.20 | 47.00 | 248.80 | 67.20 | 62.20 | 20.80 | 13.00 | 8.60 | 7.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 73.00 | 89.40 | 466.80 | 522.40 | 436.80 | 185.00 | 76.40 | 44.60 | 27.40 | 20.90 |
High Price
|
|||
| 215 | 241 | 530 | 965 | 1,000 | 560 | 365 | 275 | 275 | 80 |
Employees
|
|||
| 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 3 |
Revenue/Emp
|
|||
| 130 | 181 | 229 | 430 | 614 | 583 | 369 | 307 | 229 | 214 |
Revenue
|
|||
| 73.58% | 75.18% | 76.20% | 77.66% | 78.59% | 79.20% | 65.68% | 53.94% | 35.60% | 56.57% |
Gross Margin
|
|||
| (76) | (55) | (116) | (22) | (17) | 11 | (104) | (54) | (77) | (36) |
EBT
|
|||
| (58.72%) | (30.27%) | (50.76%) | (5.23%) | (2.81%) | 1.94% | (28.12%) | (17.49%) | (33.77%) | (16.87%) |
EBT Margin
|
|||
| (86) | (68) | (116) | (23) | (18) | 8 | (106) | (59) | (82) | (39) |
Net Income
|
|||
| 9 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Depreciation
|
|||
| 12.28 | 13.38 | 15.42 | 25.09 | 32.17 | 29.45 | 18.41 | 15.06 | 11.13 | 10.30 |
Revenue/Sh
|
|||
| (8.20) | (5.00) | (7.80) | (1.40) | (1.00) | 0.40 | (5.20) | (3.00) | (4.00) | (1.87) |
Earnings/Sh
|
|||
| (6.78) | (2.43) | (6.37) | (0.55) | (1.14) | (3.36) | (8.98) | 0.34 | (1.51) | 0.32 |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | (0.14) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (6.78) | (2.43) | (6.38) | (0.69) | (1.15) | (3.36) | (8.98) | 0.34 | (1.51) | 0.32 |
Free CF/Sh
|
|||
| (0.85) | (4.81) | 10.25 | 35.52 | 32.87 | 33.69 | 29.68 | 27.09 | 23.66 | 22.13 |
Book Value/Sh
|
|||
| 11 | 14 | 15 | 17 | 19 | 20 | 20 | 20 | 21 | 21 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 130.22 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 5.03 | 6.34 | 17.65 | 17.09 | 3.04 | 2.29 | 1.29 | 1.18 | 0.88 | 1.36 |
PS Ratio
|
|||
| 0.00 | 0.00 | 31.00 | 12.52 | 2.98 | 2.00 | 0.80 | 0.66 | 0.41 | 0.63 |
PB Ratio
|
|||
| 5.17 | 6.60 | 16.91 | 15.72 | 2.23 | 1.52 | 0.51 | 0.20 | (0.32) | 0.03 |
EV/Sales
|
|||
| (9.36) | (36.41) | (40.89) | (570.13) | (62.37) | (13.34) | (1.04) | 8.82 | 2.39 | 0.85 |
EV/FCF
|
|||
| (72) | (33) | (95) | (9) | (22) | (67) | (180) | 7 | (31) | 7 |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | (2) | 0 | 0 | (1) | 0 | — | — |
Capex
|
|||
| (72) | (33) | (95) | (12) | (22) | (67) | (180) | 7 | (31) | 7 |
FCF
|
|||
| 70 | 45 | 221 | 613 | 572 | 508 | 430 | 466 | 415 | 455 |
Working Cap'
|
|||
| 116 | 123 | 80 | 59 | 10 | 11 | 20 | — | — | — |
Total Debt
|
|||
| 18 | 48 | (170) | (589) | (495) | (447) | (290) | (321) | (295) | (303) |
Net Debt
|
|||
| (9) | (65) | 152 | 608 | 628 | 667 | 595 | 552 | 486 | 459 |
Sh' Equity
|
|||
| (50.76%) | (41.31%) | (42.55%) | (3.57%) | (1.95%) | 0.76% | (10.83%) | (6.88%) | (10.83%) | (5.72%) |
ROA
|
|||
| (480.23%) | 0.00% | 0.00% | (80.85%) | (9.26%) | 2.98% | (21.66%) | (18.29%) | (29.94%) | (20.04%) |
ROIC
|
|||
| 93.18% | 110.45% | (567.80%) | (6.32%) | (2.97%) | 1.19% | (16.76%) | (10.30%) | (15.83%) | (8.21%) |
ROE
|
|||
Amarin Corporation PLC peers in Drug Manufacturers General
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GRFS Grifols, S.A. | $1.9B | 8.1× | Compare |
| NSRX Nasus Pharma Ltd. | $40.8M | — | Compare |
| MIRA MIRA Pharmaceuticals, Inc. | $35.3M | 0.0× | Compare |
| SCLX Scilex Holding Company | $34.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OGN Organon & Co. | $3.6B | 17.4× | Compare |
| MDCX Medicus Pharma Ltd | $10.0M | 0.0× | Compare |
| BIIB Biogen Inc. | $33.5B | 40.1× | Compare |
| SNY Sanofi | $97.4B | 21.5× | Compare |
Amarin Corporation PLC (AMRN) key facts
- Amarin Corporation PLC (AMRN) is a Drug Manufacturers General company in the Healthcare sector, traded in the US as an ADR.
- Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
- As of September 25, 2026, AMRN traded at $13.20, a market capitalization of $283.6 million.
- Return on equity was −8.21% and debt-to-equity 0.00.
Amarin Corporation PLC (AMRN) Latest News
31 Aug
Amarin presented new REDUCE-IT and mechanistic data at the European Society of Cardiology Congress 2026. Conference data updates can moderately affect Amarin's scientific standing and investor views without immediate major financial shifts.
28 Aug
REDUCE-IT legacy analysis at ESC Congress 2026 shows persistent cardiovascular benefits after icosapent ethyl treatment cessation in adherent patients. Positive legacy data on icosapent ethyl may moderately improve market perception and company outlook.
7 Aug
Amarin (AMRN) held its Q2 2026 earnings call, covering financial results, operational updates, and forward outlook for the company. Quarterly earnings calls typically offer financial metrics and guidance that can shift near-term stock sentiment without guaranteeing major strategic shifts.
29 Jul
Amarin reports 2026 second quarter financial results highlighting early success of its fully partnered international commercial strategy and continued leading U.S. market presence. Positive quarterly results signal successful international expansion and U.S. dominance, positioning the company for stronger future performance.
Amarin Corp PLC reported Q2 2026 earnings with strategic growth initiatives underway despite revenue challenges. Earnings results show mixed signals from revenue pressure offset by growth plans that may affect near-term performance and sentiment.
Amarin reported Q2 earnings above estimates with revenues missing targets. Mixed Q2 earnings beat and revenue shortfall indicate moderate effects on AMRN trajectory.
Amarin Corporation PLC reports second-quarter results highlighting momentum gains in its partnered international strategy. Quarterly results and international strategy updates indicate moderate effects on financial performance and market positioning.
Amarin Q2 earnings call highlighted company financial results, operational updates and strategic outlook. Q2 earnings updates typically affect near-term sentiment and trading without guaranteeing major long-term shifts.
5 Jun
Generic drugmakers gain key victory in ‘skinny label’ patent case against Amarin Corporation PLC. Patent case victory enables generic competition that can reduce Amarin product sales and market position.
4 Jun
Hikma commented on the Supreme Court's unanimous decision in its favor. Supreme Court win for Hikma enables generic entry that directly reduces Amarin revenue and market share.
Supreme Court rules against Amarin in 'Skinny Label' patent case. Supreme Court loss exposes Amarin products to expanded generic competition and revenue erosion.
Supreme Court rules against Amarin in skinny label patent case. Supreme Court loss in patent case opens door to generic competition that can cut Amarin drug sales.
21 May
Amarin refines its fair value estimate and updates the company outlook to reflect shifting strategic priorities and market conditions. Refined fair value and outlook adjustments can moderately influence investor sentiment and near-term stock performance.
8 May
Amarin Corporation PLC (AMRN) reported Q1 loss wider than expected, while revenues beat estimates. Mixed Q1 earnings with wider loss but revenue beat moderately affect financial performance and market sentiment.
5 May
Amarin Corporation PLC (AMRN) receives analyst rating upgrade to Strong Buy, highlighting positive outlook on its cardiovascular drug portfolio and market potential. Analyst upgrade to Strong Buy boosts investor sentiment and could significantly lift stock performance amid focus on Amarin's key products.
1 May
AMRN Q1 earnings matched estimates despite revenues missing expectations; 2026 outlook raised. Q1 earnings met estimates and 2026 outlook raised despite revenue shortfall, suggesting moderate influence on financial performance and investor sentiment.
30 Apr
Amarin Corp PLC (AMRN) Q1 2026 earnings call highlights revenue growth and market expansion. Revenue growth and market expansion represent major strategic progress boosting financial performance and investor sentiment.
Amarin reported a narrower-than-expected Q1 loss with sales increasing year-over-year. Narrower Q1 loss than expected and year-over-year sales growth positively affect financial performance but remain limited in scope.
29 Apr
Amarin Corporation PLC (AMRN) released Q1 earnings call highlights, detailing financial results, operational updates, and forward-looking guidance amid ongoing commercialization of cardiovascular drug Vascepa. Q1 earnings highlights disclose financial performance, revenue updates, and strategic shifts that significantly influence AMRN's trajectory and investor sentiment.
Amarin Corporation PLC (AMRN) latest earnings report shows narrowing losses while advancing partner-led growth strategy. Narrowing losses signal financial improvement and partner-led strategy supports moderate growth momentum for AMRN.
Amarin Corporation PLC (AMRN) reported first quarter 2026 financial results. Quarterly financial results reporting impacts financial performance and investor sentiment moderately.
23 Apr
AMRX announces buyout of Kashiv BioSciences and reports solid Q1 preliminary results. Buyout of Kashiv BioSciences is a major strategic acquisition enhancing product pipeline, paired with strong Q1 results to drive significant positive impact on AMRN's trajectory and investor sentiment.
21 Apr
Amarin Corporation PLC (AMRN) released the transcript of its Q2 2025 earnings call. Q2 2025 earnings transcript details financial results, strategic updates, and guidance that significantly influence AMRN's stock trajectory and investor sentiment.
Amarin (AMRN) released Q3 2025 earnings call transcript detailing financial results, revenue updates, pipeline progress, and management guidance. Q3 2025 earnings transcript discloses financial performance, strategic updates, and forward guidance capable of significantly shifting AMRN's market trajectory and investor sentiment.
8 Apr
ACC Scientific Sessions 2026 emphasize need for complementary therapies including icosapent ethyl (IPE) to treat elevated triglycerides and reduce cardiovascular risk. ACC 2026 endorsement of IPE validates Amarin's core product for CV risk reduction, likely enhancing investor sentiment and market positioning.
Amarin (AMRN) story evolves with analysts holding steady US$12 price target amid emerging new guidelines. Steady US$12 target and new guidelines point to moderately noticeable influence on AMRN's financial performance and competitive positioning.
18 Mar
Amarin Corporation PLC highlights the guideline-recommended role of icosapent ethyl in managing cardiovascular risk following the release of the updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline. Updated guidelines recommending icosapent ethyl boost Amarin's product adoption and market positioning in cardiovascular risk management.
16 Mar
Amarin Corporation PLC to present new REDUCE-IT data on patients at extreme cardiovascular risk and in vitro research on eicosapentaenoic acid (EPA)'s mechanistic effects on lipoprotein(a) [Lp(a)] oxidation at the American College of Cardiology’s Annual Scientific Session & Expo. New subgroup data from the pivotal REDUCE-IT trial and mechanistic EPA research on Lp(a) at a major cardiology conference likely to significantly enhance Amarin's investor sentiment and competitive positioning in CV therapeutics.
11 Mar
Amarin Corporation (AMRN) story shifts as analysts rebuild models converging on a US$12 price target. Analyst model rebuilds centering on US$12 target signal major valuation shift and investor sentiment change for Amarin.
7 Mar
Amarin Corporation PLC (AMRN) faces severe investment risks from impending patent expirations on key drugs and escalating competition from generics and rivals, making the stock highly unappealing. Patent expirations and rising competition threaten Amarin's revenue dominance and market position profoundly.